Filter

Refine by subject

Refine by date

—
  • Print
  • Save
  • Print

Diagnosis and Treatment > Medication

You are looking at 1 - 1 of 1 items for :

  • Pasireotide x
Clear All
Chiara Baratelli Dipartimento di Oncologia, Oncologia Medica

Search for other papers by Chiara Baratelli in
Google Scholar
PubMed Close
,
Maria Pia Brizzi Dipartimento di Oncologia, Oncologia Medica

Search for other papers by Maria Pia Brizzi in
Google Scholar
PubMed Close
,
Marco Tampellini Dipartimento di Oncologia, Oncologia Medica

Search for other papers by Marco Tampellini in
Google Scholar
PubMed Close
,
Giorgio Vittorio Scagliotti Dipartimento di Oncologia, Oncologia Medica

Search for other papers by Giorgio Vittorio Scagliotti in
Google Scholar
PubMed Close
,
Adriano Priola SCDU Radiologia

Search for other papers by Adriano Priola in
Google Scholar
PubMed Close
,
Massimo Terzolo Dipartimento di Scienze Cliniche e Biologiche, Medicina Interna, Università di Torino, Azienda Ospedaliero Universitaria San Luigi Gonzaga, Regione Gonzole 10, 10043 Orbassano, Italy

Search for other papers by Massimo Terzolo in
Google Scholar
PubMed Close
,
Anna Pia Dipartimento di Scienze Cliniche e Biologiche, Medicina Interna, Università di Torino, Azienda Ospedaliero Universitaria San Luigi Gonzaga, Regione Gonzole 10, 10043 Orbassano, Italy

Search for other papers by Anna Pia in
Google Scholar
PubMed Close
, and
Alfredo Berruti Dipartimento di Specialità Medico-Chirurgiche, Scienze Radiologiche e Sanità Pubblica Università di Brescia, Oncologia Medica, Azienda Ospedaliera Spedali Civili, Brescia, Italy

Search for other papers by Alfredo Berruti in
Google Scholar
PubMed Close

Summary

Insulinoma is a rare form of insulin-secreting pancreatic islet cell neuroendocrine (NE) tumor. The medical treatment of the malignant NE disease of the pancreas deeply changed in the last years, thanks to the introduction of new target molecules, as everolimus. Even if the exact mechanism is not actually known, one of the side effects of everolimus, hyperglycemia, has been demonstrated to be useful to contrast the typical hypoglycemia of the insulinoma. We report the case of a patient with a metastatic malignant insulinoma treated with intermittent everolimus, obtaining an important improvement in the quality of life; this suggests the necessity of preclinical studies to analyze the cellular pathways involved in insulin-independent gluconeogenesis.

Learning points

  • Effect of somatostatin analogs is long-lasting in the control of functioning NE tumors.

  • Persistent everolimus control of hypoglycemia despite serum insulin levels and disease progression.

  • Open issue: are disease progression and the increase in serum markers the only valid criteria to reject a treatment?

Taxonomy:
Clinical Overview, Gland/Organ, Pancreas, Topic, Endocrine-related cancer, Hormone, Insulin, Condition/ Syndrome, Hypoglycaemia, Insulinoma, Metastatic tumour, Patient Demographics, Age, Adolescent/young adult, Gender, Male, Ethnicity, White, Country of Treatment, Italy, Diagnosis and Treatment, Signs and Symptoms, Liver masses, Investigation, CT scan, Glucose (blood), Insulin, SPECT scan, Intervention, Radiotherapy, Medication, Carboplatin, Diazoxide, Everolimus, Glucagon, Glucose, Octreotide, Pasireotide, Somatostatin analogues, Related Disciplines, Gastroenterology, Publication Details, Case Report Type, Unusual effects of medical treatment
DOI:
https://doi.org/10.1530/EDM-14-0047
Volume/Issue:
Volume 2014: Issue 1
Open access